Helus Pharma appointed Michael Halstead, formerly President of Intra-Cellular Therapies, as CEO to lead the company through late-stage development and commercialization. The change is directionally positive for execution credibility, but no financial targets or milestones were specified.
Helus Pharma appointed Michael Halstead, formerly President of Intra-Cellular Therapies, as CEO to lead the company through late-stage development and commercialization. The change is directionally positive for execution credibility, but no financial targets or milestones were specified.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.08
